Insights

Publication | BRG white paper

Growth of the 340B Program

November 2014

Aaron Vandervelde writes about trends and topics surrounding the 340B drug program, including the forecast of future trends.

Read the paper.

Professionals

Related Professionals

Aaron Vandervelde

Managing Director

Washington, DC